Compare Intel Corp (INTC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs TransMedics Group Inc — how do they compare? Intel Corp trades at $105.05 (market cap $487.82B), while TransMedics Group Inc trades at $74.85 (market cap $2.54B). The key difference: Intel Corp is far larger — about 192.1× TransMedics Group Inc's market cap, and Intel Corp pays a 2.24% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| INTC | TMDX | |
|---|---|---|
Market Cap | $487.82B | $2.54B |
Volume | 43,552,012 | — |
Sector | Technology | Technology |
52-Week High | $140.94 | $150.42 |
52-Week Low | $19.31 | $61.99 |
Enterprise Value | $500.07B | $2.94B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $97.87, up 2.97% on the day, with technical indicators showing a bullish overall signal despite mixed moving averages. The company has beaten earnings estimates for three consecutive quarters, though it reported a net loss of -$267 million in 2025. Recent news highlights volatility in semiconductor stocks amid AI-driven market shifts, with Intel expanding its Google Cloud AI partnership to boost enterprise growth.
Intel's outlook is cautiously optimistic, supported by earnings beats and strategic AI initiatives, but risks include intense competition, margin pressures, and sector volatility. The consensus price target of $109.55 suggests potential upside, though investors must weigh financial recovery against technological challenges in a dynamic chip market.
TransMedics (TMDX) trades at $73.47, down 0.69% with neutral technical signals. The stock shows strong profitability with 27% net margins and 45% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in European aviation logistics aims to expand the Organ Care System platform. Analyst consensus remains bullish with a $108.71 price target representing 48% upside potential.
Long-term growth prospects appear solid given TMDX's expanding transplant ecosystem, but near-term margin pressure from expansion investments and execution risks warrant caution. The company maintains competitive advantages in organ transplant logistics, though increased spending and competitive threats from alternatives like Strata Critical Medical present headwinds for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
